Odonate Therapeutics (ODT) Announces Proposed Common Share Offering of Approx. $100M

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has commenced an underwritten public offering of approximately $100 million of shares of its common stock. In addition, Odonate has granted the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock. All of the shares of common stock to be sold in the underwritten public offering are being offered by Odonate.

Odonate intends to use the proceeds from the proposed underwritten public offering of its shares of common stock for development and regulatory activities relating to tesetaxel, as well as for working capital and general corporate purposes.

Jefferies and Cowen are acting as joint book-running managers. LifeSci Capital is acting as lead manager for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on February 28, 2019.

You May Also Be Interested In

• AiRWA receives Nasdaq deficiency notice over late 10-K filing
• ENvue Medical sets 1-for-12 reverse stock split effective Sept. 1
• Klarna CEO buys ~$10M in company shares